"Seasonal fluctuations in pharmaceutical sales are common, particularly in cold, flu and allergy seasons," said Philip Thornton , CEO of Drugs.com. "This year's flu activity, which started about four weeks early and was relatively severe, is evident in the Tamiflu numbers."
Top Five Sales Losses, Q1 2013Drug Name
-5.11%The drugs with the top five dollar losses for the quarter each forfeit between $28 and $46 million. Avonex and Incivek make repeat appearances from last quarter.
Modafinil, the generic version of Teva's Provigil used to improve wakefulness, was launched in Q2 2012 but sales have since slowed. Sales of Biogen Idec's Avonex continue to slide in response to the approval of oral multiple sclerosis drugs, which might include their own Tecfidera. Incivek sales also dropped -- new Hepatitis C approvals are in the wings, and a serious skin reaction resulted in a newly penned Box Warning for Incivek.
Detailed data on the top 100 drugs can be accessed at:
About Drugs.comDrugs.com is the leading online drug information resource with over nine million unique visitors per month (ComScore, March 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as persona
Copyright©2012 PR Newswire.
All rights reserved